|
1
|
Agarwal S, Sane R, Oberoi R, Ohlfest JR
and Elmquist WF: Delivery of molecularly targeted therapy to
malignant glioma, a disease of the whole brain. Expert Rev Mol Med.
13:e172011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berens ME and Giese A: ‘those left behind’
Biology and oncology of invasive glioma cells. Neoplasia.
1:208–219. 1999.
|
|
3
|
Régnard P, Bräuer-Krisch E, Troprès I,
Keyriläinen J, Bravin A and Le Duc G: Enhancement of survival of 9L
gliosarcoma bearing rats following intracerebral delivery of drugs
in combination with microbeam radiation therapy. Eur J Radiol.
68:S151–S155. 2008.PubMed/NCBI
|
|
4
|
Spence AM, Rasey JS, Dwyer-Hansen L, et
al: Toxicity, biodistribution and radioprotective capacity of
L-homocysteine thiolactone in CNS tissues and tumors in rodents:
comparison with prior results with phosphorothioates. Radiother
Oncol. 35:216–226. 1995. View Article : Google Scholar
|
|
5
|
Bernstein M, Cabantog AM, Glen J, Stiver S
and Mikulis D: Tirilazad does not protect rat brain from
brachytherapy-induced injury. Surg Neurol. 45:482–489. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marks P, Rifkind RA, Richon VM, Breslow R,
Miller T and Kelly WK: Histone deacetylases and cancer: causes and
therapies. Nat Rev Cancer. 1:194–202. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnstone RW: Histone-deacetylase
inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug
Discov. 1:287–299. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hess-Stumpp H: Histone deacetylase
inhibitors and cancer: from cell biology to the clinic. Eur J Cell
Biol. 84:109–121. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Camphausen K, Scott T, Sproull M and
Tofilon PJ: Enhancement of xenograft tumor radiosensitivity by the
histone deacetylase inhibitor MS-275 and correlation with histone
hyperacetylation. Clin Cancer Res. 10(18 Pt 1): 6066–6071. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sheehan J, Ionescu A, Pouratian N, et al:
Use of trans sodium crocetinate for sensitizing glioblastoma
multiforme to radiation: laboratory investigation. J Neurosurg.
108:972–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marks PA and Xu WS: Histone deacetylase
inhibitors: Potential in cancer therapy. J Cell Biochem.
107:600–608. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shabason JE, Tofilon PJ and Camphausen K:
Grand rounds at the National Institutes of Health: HDAC inhibitors
as radiation modifiers, from bench to clinic. J Cell Mol Med.
15:2735–2744. 2011. View Article : Google Scholar
|
|
13
|
Peterson GM and Naunton M: Valproate: a
simple chemical with so much to offer. J Clin Pharm Ther.
30:417–421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Phiel CJ, Zhang F, Huang EY, Guenther MG,
Lazar MA and Klein PS: Histone deacetylase is a direct target of
valproic acid, a potent anticonvulsant, mood stabilizer, and
teratogen. J Biol Chem. 276:36734–36741. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Göttlicher M, Minucci S, Zhu P, et al:
Valproic acid defines a novel class of HDAC inhibitors inducing
differentiation of transformed cells. EMBO J. 20:6969–6978.
2001.PubMed/NCBI
|
|
16
|
Marks PA, Miller T and Richon VM: Histone
deacetylases. Curr Opin Pharmacol. 3:344–351. 2003. View Article : Google Scholar
|
|
17
|
Chen Y, Tsai YH and Tseng SH: Valproic
acid affected the survival and invasiveness of human glioma cells
through diverse mechanisms. J Neurooncol. 109:23–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Camphausen K and Tofilon PJ: Inhibition of
histone deacetylation: a strategy for tumor radiosensitization. J
Clin Oncol. 25:4051–4056. 2007. View Article : Google Scholar
|
|
19
|
Camphausen K, Cerna D, Scott T, et al:
Enhancement of in vitro and in vivo tumor cell radiosensitivity by
valproic acid. Int J Cancer. 114:380–386. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Camphausen K, Burgan W, Cerra M, et al:
Enhanced radiation-induced cell killing and prolongation of
gammaH2AX foci expression by the histone deacetylase inhibitor
MS-275. Cancer Res. 64:316–321. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JH, Shin JH and Kim IH: Susceptibility
and radiosensitization of human glioblastoma cells to trichostatin
A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys.
59:1174–1180. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y and Jung M, Dritschilo A and Jung
M: Enhancement of radiation sensitivity of human squamous carcinoma
cells by histone deacetylase inhibitors. Radiat Res. 161:667–674.
2004. View
Article : Google Scholar
|
|
23
|
Geng L, Cuneo KC, Fu A, Tu T, Atadja PW
and Hallahan DE: Histone deacetylase (HDAC) inhibitor LBH589
increases duration of gamma-H2AX foci and confines HDAC4 to the
cytoplasm in irradiated non-small cell lung cancer. Cancer Res.
66:11298–11304. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Folkvord S, Ree AH, Furre T, Halvorsen T
and Flatmark K: Radiosensitization by SAHA in experimental
colorectal carcinoma models - in vivo effects and relevance of
histone acetylation status. Int J Radiat Oncol Biol Phys.
74:546–552. 2009. View Article : Google Scholar
|
|
25
|
Chen X, Wong P, Radany E and Wong JY: HDAC
inhibitor, valproic acid, induces p53-dependent radiosensitization
of colon cancer cells. Cancer Biother Radiopharm. 24:689–699. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Munshi A, Kurland JF, Nishikawa T, et al:
Histone deacetylase inhibitors radiosensitize human melanoma cells
by suppressing DNA repair activity. Clin Cancer Res. 11:4912–4922.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baschnagel A, Russo A, Burgan WE, et al:
Vorinostat enhances the radiosensitivity of a breast cancer brain
metastatic cell line grown in vitro and as intracranial xenografts.
Mol Cancer Ther. 8:1589–1595. 2009. View Article : Google Scholar
|
|
28
|
López-Soto A, Folgueras AR, Seto E and
Gonzalez S: HDAC3 represses the expression of NKG2D ligands ULBPs
in epithelial tumour cells: potential implications for the
immunosurveillance of cancer. Oncogene. 28:2370–2382.
2009.PubMed/NCBI
|
|
29
|
Benitez JA, Arregui L, Cabrera G and
Segovia J: Valproic acid induces polarization, neuronal-like
differentiation of a subpopulation of C6 glioma cells and
selectively regulates transgene expression. Neuroscience.
156:911–920. 2008. View Article : Google Scholar
|
|
30
|
Yu H: Typical cell signaling response to
ionizing radiation: DNA damage and extranuclear damage. Chin J
Cancer Res. 24:83–89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Santivasi WL and Xia F: The role and
clinical significance of DNA damage response and repair pathways in
primary brain tumors. Cell Biosci. 3:102013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Groselj B, Sharma NL, Hamdy FC, Kerr M and
Kiltie AE: Histone deacetylase inhibitors as radiosensitisers:
effects on DNA damage signalling and repair. Br J Cancer.
108:748–754. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cui YH, Liang HJ, Zhang QQ, et al:
Radiosensitivity enhancement by arsenic trioxide in conjunction
with hyperthermia in the EC-1 esophageal carcinoma cell line. Asian
Pac J Cancer Prev. 13:1693–1697. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Munshi A, Tanaka T, Hobbs ML, Tucker SL,
Richon VM and Meyn RE: Vorinostat, a histone deacetylase inhibitor,
enhances the response of human tumor cells to ionizing radiation
through prolongation of gamma-H2AX foci. Mol Cancer Ther.
5:1967–1974. 2006. View Article : Google Scholar
|
|
36
|
Zhang Y, Adachi M, Zhao X, Kawamura R and
Imai K: Histone deacetylase inhibitors FK228,
N-(2-aminophenyl)-4-[N-(pyri-
din-3-yl-methoxycarbonyl)amino-methyl]benzamide and
m-carboxycinnamic acid bis-hydroxamide augment radiation-induced
cell death in gastrointestinal adenocarcinoma cells. Int J Cancer.
110:301–308. 2004.PubMed/NCBI
|
|
37
|
Wolter KG, Hsu YT, Smith CL, Nechushtan A,
Xi XG and Youle RJ: Movement of Bax from the cytosol to
mitochondria during apoptosis. J Cell Biol. 139:1281–1292. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Putcha GV, Deshmukh M and Johnson EM Jr:
BAX translocation is a critical event in neuronal apoptosis:
regulation by neuroprotectants, BCL-2, and caspases. J Neurosci.
19:7476–7485. 1999.PubMed/NCBI
|
|
39
|
Thomas A, El Rouby S, Reed JC, et al:
Drug-induced apoptosis in B-cell chronic lymphocytic leukemia:
relationship between p53 gene mutation and bcl-2/bax proteins in
drug resistance. Oncogene. 12:1055–1062. 1996.PubMed/NCBI
|
|
40
|
Yanase N, Takada E, Yoshihama I, Ikegami H
and Mizuguchi J: Participation of Bax-alpha in IFN-alpha-mediated
apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res.
18:855–861. 1998. View Article : Google Scholar
|
|
41
|
Lin HI, Lee YJ, Chen BF, et al:
Involvement of Bcl-2 family, cytochrome c and caspase 3 in
induction of apoptosis by beauvericin in human non-small cell lung
cancer cells. Cancer Lett. 230:248–259. 2005.PubMed/NCBI
|
|
42
|
Kim DS, Jeon SE, Jeong YM, Kim SY, Kwon SB
and Park KC: Hydrogen peroxide is a mediator of indole-3-acetic
acid/horseradish peroxidase-induced apoptosis. FEBS Lett.
580:1439–1446. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zuliani T, Obriot H, Tual M, et al:
Variable Bax antigenicity is linked to keratinocyte position within
epidermal strata and UV-induced apoptosis. Exp Dermatol.
17:125–132. 2008. View Article : Google Scholar
|
|
44
|
Park SK, Kang H and Kwon CH:
Caspase-dependent cell death mediates potent cytotoxicity of
sulfide derivatives of 9-anilinoacridine. Anticancer Drugs.
19:381–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
